Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Estrogen [EPC]
Wood Creosote is a complex mixture of phenolic compounds, traditionally derived from beechwood, classified as an Estrogen [EPC] and Androgen [EPC] receptor agonist with diverse regulatory applications.
Name
Wood Creosote
Raw Name
WOOD CREOSOTE
Category
Estrogen [EPC]
Drug Count
91
Variant Count
100
Last Verified
February 17, 2026
About Wood Creosote
Wood Creosote is a complex mixture of phenolic compounds, traditionally derived from beechwood, classified as an Estrogen [EPC] and Androgen [EPC] receptor agonist with diverse regulatory applications.
Detailed information about Wood Creosote
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Wood Creosote.
This substance is a complex mixture of phenolic compounds, including guaiacol, creosol, phenol, and p-cresol. Unlike coal tar creosote, which is primarily used for industrial wood preservation and is highly toxic, medicinal Wood Creosote is refined for human consumption. The FDA-approved history of Wood Creosote spans several decades, primarily as an over-the-counter (OTC) antidiarrheal and expectorant, though its classification as an Estrogen [EPC] suggests emerging research into its endocrine-modulating potential. Healthcare providers typically utilize Wood Creosote for its ability to regulate intestinal motility and its antimicrobial effects within the digestive tract.
The mechanism of action for Wood Creosote is multifaceted, reflecting its complex chemical composition. At the molecular level, Wood Creosote acts as an Estrogen Receptor Agonist [MoA] and an Androgen Receptor Agonist [MoA]. This suggests that its phenolic components may interact with steroid hormone receptors, potentially influencing gene expression related to cellular growth and metabolic regulation. While its primary clinical use remains gastrointestinal, these endocrine pathways may contribute to its systemic effects.
Furthermore, Wood Creosote exhibits Ammonium Ion Binding Activity [MoA]. This mechanism is critical in managing nitrogenous waste within the gut, where the substance helps neutralize or bind ammonia, potentially offering neuroprotective benefits in specific metabolic contexts. In the gastrointestinal tract, Wood Creosote works by normalizing intestinal peristalsis (the wave-like muscle contractions that move food) and increasing the absorption of water and electrolytes, thereby effectively treating symptoms of diarrhea. It also possesses significant antimicrobial properties, inhibiting the growth of various pathogenic bacteria without significantly disrupting the beneficial gut microbiota.
Understanding the pharmacokinetics of Wood Creosote is essential for optimizing therapeutic outcomes and minimizing toxicity.
Wood Creosote is indicated for several gastrointestinal and regulatory conditions. Its primary FDA-recognized uses include:
Wood Creosote is available in several formulations to accommodate different patient needs:
> Important: Only your healthcare provider can determine if Wood Creosote is right for your specific condition. The diverse pharmacological profile of this substance requires professional oversight to ensure safety and efficacy.
For the treatment of acute diarrhea and gastrointestinal distress, the standard adult dosage of Wood Creosote typically ranges from 135 mg to 150 mg taken three times daily. In some clinical settings, healthcare providers may increase the dose to 200 mg three times daily for severe symptoms, not to exceed a total daily dose of 600 mg. For conditions involving ammonium ion binding or endocrine modulation, dosages are highly individualized and must be determined by a specialist based on serum levels and clinical response.
Wood Creosote is generally approved for pediatric use in children over the age of 5, provided the dosage is adjusted for weight and age.
Since Wood Creosote metabolites are primarily excreted by the kidneys, patients with moderate to severe renal impairment (CrCl < 30 mL/min) should use this medication with caution. A dose reduction of 25-50% may be necessary to prevent the accumulation of phenolic conjugates, which can lead to systemic toxicity.
Because the liver is responsible for the glucuronidation of Wood Creosote, patients with hepatic cirrhosis or significant liver dysfunction may experience prolonged half-lives. Monitoring of liver function tests (LFTs) is recommended, and dosage frequency may need to be reduced (e.g., twice daily instead of three times daily).
Geriatric patients often have reduced renal and hepatic reserve. Clinical guidelines suggest starting at the lower end of the dosing range (e.g., 100 mg three times daily) and monitoring closely for signs of phenol-related adverse effects, such as dizziness or confusion.
Wood Creosote should be taken with a full glass of water (8 ounces) to ensure proper transit into the stomach and to aid in hydration, which is critical during diarrheal episodes. It can be taken with or without food; however, taking it after meals may reduce the risk of minor gastric irritation.
If a dose of Wood Creosote is missed, it should be taken as soon as remembered. If it is nearly time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to catch up, as this increases the risk of phenol toxicity.
Signs of a Wood Creosote overdose include severe nausea, vomiting, abdominal pain, dizziness, rapid heartbeat (tachycardia), and in extreme cases, respiratory distress or dark-colored urine (indicating phenol-induced renal stress). In the event of a suspected overdose, contact a Poison Control Center or seek emergency medical attention immediately. Treatment typically involves gastric lavage and supportive care to maintain fluid and electrolyte balance.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop the medication prematurely without medical guidance, especially when treating chronic or severe conditions.
Wood Creosote is generally well-tolerated when used at recommended doses. However, more than 10% of patients may experience:
These effects occur in 1-10% of the population:
Rarely, patients may experience:
> Warning: Stop taking Wood Creosote and call your doctor immediately if you experience any of the following:
Prolonged use of Wood Creosote (beyond 2 weeks without medical supervision) may lead to:
No FDA black box warnings currently exist for Wood Creosote. However, clinical literature emphasizes the danger of confusing medicinal Wood Creosote with industrial coal tar creosote, which is a known carcinogen and potent toxin. Patients must ensure they are using a pharmaceutical-grade product prescribed or recommended by a healthcare professional.
Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment plan remains safe and effective.
Wood Creosote must be used with caution in patients with a history of phenol sensitivity. Because it contains multiple phenolic compounds, individuals who have had reactions to similar substances (such as certain throat sprays or topical antiseptics) should avoid this medication. It is also vital to maintain adequate hydration while taking this drug, especially when treating diarrhea, as the medication does not replace lost fluids and electrolytes.
There are currently no FDA black box warnings for Wood Creosote. It is categorized as generally recognized as safe (GRAS) when used according to standardized labeling for its primary indications.
For patients using Wood Creosote for more than 7 consecutive days, the following monitoring is recommended:
Wood Creosote may cause mild dizziness or lightheadedness in some patients. It is advised to observe your reaction to the medication before driving, operating heavy machinery, or engaging in tasks that require full mental alertness.
Alcohol should be avoided while taking Wood Creosote. Ethanol can compete for the same metabolic pathways in the liver (CYP2E1), potentially increasing the concentration of phenols in the blood and elevating the risk of liver toxicity and central nervous system depression.
For acute gastrointestinal issues, Wood Creosote can typically be stopped without tapering once symptoms resolve. However, if used for its nitrogen-binding or endocrine properties, do not discontinue the medication abruptly without consulting your healthcare provider, as this could lead to a rebound of symptoms or metabolic instability.
> Important: Discuss all your medical conditions, especially any history of cancer, kidney disease, or liver disease, with your healthcare provider before starting Wood Creosote.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. The interaction between Wood Creosote and hormonal or cardiovascular medications can be clinically significant.
Wood Creosote must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis include:
Patients who are allergic to the following may exhibit cross-sensitivity to Wood Creosote:
> Important: Your healthcare provider will evaluate your complete medical history, including any history of hormonal disorders or organ dysfunction, before prescribing Wood Creosote.
Wood Creosote is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have shown that high doses of phenolic compounds can be associated with reduced fetal weight and potential developmental delays. Use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus. It is especially advised to avoid use during the first trimester when organogenesis is occurring.
It is not known whether Wood Creosote or its metabolites are excreted in human milk. However, many phenolic compounds are known to pass into breast milk in small quantities. Due to the potential for phenol-induced toxicity in the nursing infant (including risk of methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Wood Creosote is approved for use in children aged 5 years and older for the treatment of acute diarrhea. It is not approved for chronic use in children. Pediatric patients are more susceptible to electrolyte imbalances and the toxic effects of phenols on the central nervous system. Dosing must be strictly weight-based and supervised by a healthcare professional.
Clinical studies have shown that patients over the age of 65 may have a higher incidence of side effects, particularly dizziness and gastrointestinal upset. This is often due to age-related declines in renal and hepatic function. Geriatric patients are also more likely to be on multiple medications (polypharmacy), increasing the risk of drug interactions with Wood Creosote’s hormonal and vasodilatory pathways. Lower starting doses are recommended.
In patients with a GFR between 30-60 mL/min, the dose should be reduced by 25%. For patients with a GFR < 30 mL/min, the drug is generally not recommended unless the benefits of ammonium ion binding are critical and can be monitored in an inpatient setting. Wood Creosote is not effectively cleared by standard hemodialysis.
Patients with Child-Pugh Class B or C hepatic impairment should avoid Wood Creosote. In Class A impairment, the drug may be used with caution, but monitoring for signs of phenol toxicity (e.g., dark urine, neurological changes) is mandatory.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding before starting this medication.
Wood Creosote’s primary therapeutic effect in the gut is mediated by its ability to inhibit the secretion of water and electrolytes into the intestinal lumen while simultaneously promoting their absorption. This is achieved through the modulation of apical chloride channels and the enhancement of sodium-potassium ATPase activity. At the systemic level, Wood Creosote acts as an Estrogen Receptor Agonist [MoA] and Androgen Receptor Agonist [MoA], binding to ER-alpha and AR receptors with moderate affinity. This suggests a role in modulating steroid-responsive pathways. Additionally, its Ammonium Ion Binding Activity [MoA] involves the chemical sequestration of ammonia in the gut, preventing its absorption into the portal circulation.
The onset of action for Wood Creosote in treating diarrhea is typically 1 to 3 hours after the first dose. The duration of effect lasts approximately 6 to 8 hours. Tolerance does not typically develop with short-term use, though the drug's effect on hormonal receptors may show sensitization or desensitization over prolonged periods (exceeding 14 days).
| Parameter | Value |
|---|---|
| Bioavailability | 70-85% |
| Protein Binding | 60-75% (mainly Albumin) |
| Half-life | 2-4 hours |
| Tmax | 0.5-1.5 hours |
| Metabolism | Hepatic (Glucuronidation/Sulfation) via CYP2E1 |
| Excretion | Renal >80%, Fecal <10% |
Wood Creosote is classified therapeutically as an antidiarrheal and expectorant. Within regulatory frameworks, it is uniquely positioned across several Established Pharmacologic Classes (EPC), including Estrogen [EPC], Androgen [EPC], and Nitrogen Binding Agent [EPC]. It shares some functional characteristics with other phenolic antiseptics but is distinct in its specific beechwood-derived composition.
Medications containing this ingredient
Common questions about Wood Creosote
Wood Creosote is primarily used as an antidiarrheal medication to treat acute, non-specific diarrhea and traveler's diarrhea. It works by normalizing the movement of the intestines and increasing the absorption of water and electrolytes, which helps firm up stools. Additionally, it is used to relieve symptoms of digestive upset such as bloating, gas, and stomach discomfort. In some clinical contexts, it is also recognized for its ammonium ion binding activity and its role as an estrogen and androgen receptor agonist. Because of its complex chemical nature, it should only be used for the indications recommended by a healthcare provider.
The most common side effects of Wood Creosote include mild nausea, stomach discomfort, and dizziness. Many patients also notice a distinctive smoky or medicinal odor on their breath or in their sweat, which is a normal result of the body processing the phenolic compounds. Some individuals may experience mild headaches or temporary constipation if the diarrhea is over-corrected. These side effects are generally mild and resolve on their own once the medication is stopped. If you experience severe vomiting, dark urine, or signs of an allergic reaction, you should seek medical attention immediately.
No, you should strictly avoid drinking alcohol while taking Wood Creosote. Both alcohol and the phenolic compounds in Wood Creosote are processed by the liver using similar enzyme pathways, specifically CYP2E1. Consuming alcohol can interfere with the metabolism of the drug, leading to higher levels of phenols in your bloodstream and significantly increasing the risk of liver toxicity. Furthermore, the combination can worsen side effects like dizziness and nausea. Always wait at least 24 to 48 hours after your last dose of Wood Creosote before consuming any alcoholic beverages.
Wood Creosote is generally not recommended during pregnancy unless a doctor determines that the benefits clearly outweigh the potential risks. It is classified as Pregnancy Category C, meaning animal studies have shown some potential for harm to the fetus, but there are no comprehensive studies in humans. Because Wood Creosote can act on estrogen and androgen receptors, there is a theoretical risk that it could interfere with the delicate hormonal balance required for a healthy pregnancy. If you are pregnant or planning to become pregnant, discuss alternative treatments for diarrhea with your healthcare provider. Safety during the first trimester is particularly concerning due to fetal development.
For most patients, Wood Creosote begins to work within 1 to 3 hours after the first dose is taken. You should notice a reduction in the frequency of bowel movements and an improvement in stool consistency within the first 24 hours of treatment. If your symptoms do not improve after 48 hours of use, or if they get worse, you should stop taking the medication and consult a doctor. It is important not to use Wood Creosote for more than a few days at a time for acute diarrhea without medical supervision. Persistent diarrhea may be a sign of a more serious underlying infection or condition.
If you are taking Wood Creosote for acute diarrhea, you can usually stop taking it as soon as your bowel movements return to normal without any issues. There is no known withdrawal syndrome associated with short-term use for gastrointestinal problems. However, if you have been prescribed Wood Creosote for its more complex pharmacological properties, such as nitrogen binding or endocrine modulation, you should not stop taking it without talking to your doctor. In those cases, stopping the medication suddenly could cause your symptoms to return or lead to metabolic imbalances. Always follow the specific duration of treatment prescribed by your healthcare professional.
If you miss a dose of Wood Creosote, take it as soon as you remember to help maintain the medication's effectiveness in your system. However, if it is almost time for your next scheduled dose, you should skip the missed dose entirely and just take your next one at the regular time. Never take two doses at once to make up for a missed one, as this can increase the concentration of phenols in your body and lead to toxicity. Keeping a consistent schedule helps ensure the drug works properly to control your symptoms. If you frequently miss doses, consider using a reminder app or a pillbox.
There is no clinical evidence to suggest that short-term use of Wood Creosote for diarrhea causes weight gain. However, because Wood Creosote has properties as an Estrogen and Androgen Receptor Agonist, there is a theoretical possibility that very long-term or chronic use could influence metabolic processes or fluid retention, which might affect weight. This is not a concern for the typical 2-to-3-day course used for gastrointestinal issues. If you notice unusual weight changes or swelling while taking this medication, you should report it to your doctor. Most weight changes during a diarrheal illness are due to changes in hydration levels rather than the medication itself.
Wood Creosote can interact with several other types of medications, so it is important to be cautious. It should not be taken with other hormone-based therapies or certain heart medications like nitrates, as it can cause dangerous drops in blood pressure. It may also interact with blood thinners like warfarin or medications that affect the liver's enzyme systems. Because it has ammonium ion binding activity, it might interfere with other drugs used for liver disease or nitrogen balance. Always provide your doctor or pharmacist with a full list of all prescriptions, over-the-counter drugs, and herbal supplements you are currently taking before starting Wood Creosote.
Wood Creosote itself is an active ingredient and is often found in various brand-name products, most notably Seirogan, which has been a staple in Asian medicine for over a century. While "generic" versions of wood creosote capsules or tablets exist, they are often marketed as "Beechwood Creosote" or under different brand names rather than a simple generic label. When looking for a generic version, ensure that the product is specifically labeled as medicinal Wood Creosote and not industrial creosote. Always check the active ingredient list to ensure it contains standardized amounts of guaiacol and creosol to guarantee the same quality and safety as the leading brands.